• Home Blog Tag Moderate to severe plaque psoriasis

Moderate to Severe Plaque Psoriasis

Latest Developments in the US Psoriasis Treatment Market

Apr 19, 2024

Revolutionizing Psoriasis Treatment: Advancements in the US Market

Pharma News for Pfizer, UCB, BioMarin

Oct 24, 2023

FDA Approves PENBRAYA for Most Common Serogroups Causing Meningococcal Disease; BIMZELX Approved Moderate to Severe Plaque Psoriasis; FDA Approves BioMarin’s VOXZOGO; FDA Fast Track Designation to ANPD001 for Parkinson’s Disease; UCB Announces FDA Approval of ZILBRYSQ; EMA Granted Orphan Drug Designation to Lisata’s LSTA1

Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper
Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper

Newsletter/Whitepaper